CHA2DS2-VASc Score Calculator
An interactive implementation of the CHA2DS2-VASc stroke risk score (Lip et al.): seven clinical factors scored 0 to 9 to estimate annual stroke risk in atrial fibrillation and guide oral anticoagulation decisions.
Answer seven questions about heart failure, hypertension, age, diabetes, prior stroke or TIA, vascular disease and sex to compute the CHA2DS2-VASc score from 0 to 9, with the corresponding published annual stroke rate. Use the result alongside bleeding risk assessment to decide about oral anticoagulation.
What is the CHA2DS2-VASc score?
The CHA2DS2-VASc score is the most widely used tool for estimating stroke risk in atrial fibrillation, and it sits at the centre of every major guideline on the topic. It was introduced by Lip and colleagues in 2010 as an improvement on the CHADS2 score, which had a large low-risk group in whom stroke still occurred more often than expected. By adding vascular disease, the 65 to 74 age band and female sex, and by giving extra weight to age 75 and above and to prior stroke, the refined score identifies truly low-risk patients more reliably and spreads the rest across a finer gradient of risk.
The clinical purpose is decision support for anticoagulation. Oral anticoagulants, whether vitamin K antagonists such as warfarin or the direct oral anticoagulants, reduce stroke risk in atrial fibrillation by roughly two-thirds, but they increase bleeding risk. The score quantifies the stroke side of that trade-off so that the decision rests on numbers rather than impression. Modern European and American guidance converges on the same practical rule: anticoagulate men at 2 or more and women at 3 or more, consider anticoagulation for men at 1 and women at 2, and withhold it when the only point is female sex.
The seven factors and their points
Each component reflects an independent predictor of thromboembolism identified in the Euro Heart Survey and subsequent validation cohorts. Congestive heart failure or objective left ventricular dysfunction scores 1 point, as does hypertension, defined pragmatically as treated or untreated elevated blood pressure. Diabetes mellitus scores 1 point. Vascular disease, meaning prior myocardial infarction, peripheral artery disease or complex aortic plaque, scores 1 point and was the key addition over CHADS2. Female sex scores 1 point.
Two factors are doubled because their association with stroke is roughly twice as strong. Age 75 years or older contributes 2 points, while age 65 to 74 contributes a single point; the two age bands are mutually exclusive, so a 78-year-old scores 2 for age, not 3. Prior stroke, transient ischaemic attack or systemic embolism contributes 2 points and is the single strongest predictor in the score. The maximum is therefore 9 points, reached by an older woman with every risk factor present.
How to interpret the score
The published annual stroke rates without anticoagulation, from the Lip validation cohorts, are: 0 points, 0 percent; 1 point, 1.3 percent; 2 points, 2.2 percent; 3 points, 3.2 percent; 4 points, 4.0 percent; 5 points, 6.7 percent; 6 points, 9.8 percent; 7 points, 9.6 percent; 8 points, 6.7 percent; and 9 points, 15.2 percent. The apparent dip at 8 points reflects small numbers in that stratum rather than a true biological pattern, and it should not influence decisions.
In practice the score is read against treatment thresholds rather than as a precise prediction. A score of 0 in a man, or 1 in a woman where the single point is sex, identifies a patient in whom anticoagulation offers no meaningful net benefit, and guidelines recommend against it. From 1 in men and 2 in women upward, the stroke risk is high enough that anticoagulation should at least be discussed, with bleeding risk, frailty, fall risk and patient values shaping the final call. At 2 in men and 3 in women, the recommendation becomes firm in the absence of absolute contraindications.
Stroke risk is only half the decision
Every guideline pairs CHA2DS2-VASc with a bleeding risk assessment, most commonly the HAS-BLED score, because the patients at highest stroke risk are often also at highest bleeding risk. The two scores share several variables, including hypertension, age and prior stroke, so they tend to move together. The correct response to a high bleeding score is not to withhold anticoagulation reflexively but to hunt for modifiable factors: bring blood pressure under control, stabilise the INR or switch to a direct oral anticoagulant with more predictable levels, review interacting drugs and alcohol use, and correct anaemia. Net clinical benefit analyses consistently show that most patients with an indication for anticoagulation still benefit even when bleeding risk is elevated.
Choice of agent is a separate decision the score does not address. Direct oral anticoagulants are preferred over warfarin for most patients with non-valvular atrial fibrillation because of their lower intracranial bleeding risk and freedom from routine monitoring, while warfarin remains the choice in moderate to severe mitral stenosis and mechanical heart valves, settings where direct agents are contraindicated. Renal function, drug interactions, cost and adherence all feed into that choice alongside the stroke and bleeding scores.
Limitations
CHA2DS2-VASc is a population-derived point score, not a personal prophecy, and its discrimination is modest, with c-statistics around 0.6. It treats each factor as present or absent, ignoring severity: well-controlled hypertension counts the same as resistant hypertension. It does not incorporate left atrial size, atrial fibrillation burden or pattern, biomarkers, or imaging findings that also predict stroke. The annual rates come from European cohorts assembled over a decade ago, and absolute event rates have drifted as background care improved. Finally, the score was validated for stroke prediction, not for deciding about left atrial appendage closure or other interventions, and it should be recalculated as risk factors accumulate with age.
References
- Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272.
- Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-180.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125-e151.
Key takeaways
- CHA2DS2-VASc sums seven factors, congestive heart failure, hypertension, age, diabetes, prior stroke or TIA, vascular disease and female sex, into a score from 0 to 9.
- Age 75 or older and prior stroke, TIA or systemic embolism each score 2 points; the two age bands are mutually exclusive.
- Published annual stroke rates without anticoagulation run from 0 percent at 0 points to 15.2 percent at 9 points.
- Guidelines recommend oral anticoagulation for men at 2 or more and women at 3 or more, and suggest considering it for men at 1 and women at 2.
- A score of 0 in men, or 1 in women where sex is the only point, generally does not warrant anticoagulation.
- Always assess bleeding risk separately, for example with HAS-BLED, and address modifiable bleeding factors rather than withholding anticoagulation by default.
Frequently asked questions
What is the CHA2DS2-VASc score used for?
The CHA2DS2-VASc score estimates the annual risk of stroke in people with atrial fibrillation who are not anticoagulated. It sums points for congestive heart failure, hypertension, age 75 or older (2 points), diabetes, prior stroke or TIA (2 points), vascular disease, age 65 to 74, and female sex, for a total of 0 to 9. Guidelines use the score to decide who should receive oral anticoagulation for stroke prevention.
At what CHA2DS2-VASc score should anticoagulation be started?
Current guidance generally recommends oral anticoagulation for men with a score of 2 or more and women with a score of 3 or more, and advises considering it for men with a score of 1 and women with a score of 2 after weighing bleeding risk and patient preference. A score of 0 in men or 1 in women where sex is the only point generally does not warrant anticoagulation. The final decision always rests with the treating clinician.
Why does female sex count as a point?
Female sex was included because observational data showed women with atrial fibrillation had higher stroke rates than men with otherwise similar risk profiles. However, female sex alone, without any other risk factor, does not raise stroke risk enough to justify anticoagulation, which is why guidelines treat a score of 1 in women where sex is the only point the same as a score of 0 in men.
Can CHA2DS2-VASc be used for atrial flutter?
Yes. Atrial flutter carries a similar thromboembolic risk to atrial fibrillation and often coexists with or degenerates into fibrillation, so guidelines apply the same CHA2DS2-VASc based anticoagulation thresholds to patients with atrial flutter.
Does the score replace bleeding risk assessment?
No. CHA2DS2-VASc estimates stroke risk only. Bleeding risk should be assessed separately, for example with the HAS-BLED score, to identify modifiable bleeding risk factors such as uncontrolled hypertension, labile INRs or interacting drugs. A high bleeding risk does not by itself cancel the indication for anticoagulation, but it prompts closer monitoring and correction of reversible factors.
How often should the score be recalculated?
Risk factors accumulate with age and new diagnoses, so the score should be reassessed at least annually and whenever the clinical picture changes, for example after a new hypertension diagnosis, a 65th or 75th birthday, or a stroke or TIA. A patient who did not meet the anticoagulation threshold last year may meet it this year.